U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H27FN4O2
Molecular Weight 398.4746
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of SUNITINIB

SMILES

CCN(CC)CCN=C(c1c(C)c(/C(/[H])=C\2/c3cc(ccc3N=C2O)F)[nH]c1C)O

InChI

InChIKey=WINHZLLDWRZWRT-ATVHPVEESA-N
InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-

HIDE SMILES / InChI

Molecular Formula C22H27FN4O2
Molecular Weight 398.4746
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including https://www.drugbank.ca/drugs/DB01268 | http://reference.medscape.com/drug/sutent-sunitinib-342201 | https://www.drugs.com/cdi/sunitinib.html | https://www.ncbi.nlm.nih.gov/pubmed/25272897 | https://www.ncbi.nlm.nih.gov/pubmed/28413468

Sunitinib (marketed as Sutent by Pfizer, and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor. Sunitinib was evaluated for its inhibitory activity against a variety of kinases and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFRa and PDGFRb), vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony-stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib adverse events are considered somewhat manageable and the incidence of serious adverse events low. The most common adverse events associated with sunitinib therapy are fatigue, diarrhea, nausea, anorexia, hypertension, yellow skin discoloration, hand-foot skin reaction, and stomatitis. In the placebo-controlled Phase III GIST study, adverse events which occurred more often with sunitinib than placebo included diarrhea, anorexia, skin discoloration, mucositis/stomatitis, asthenia, altered taste, and constipation. Dose reductions were required in 50% of the patients studied in RCC in order to manage the significant toxicities of this agent.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SUTENT

Approved Use

SUTENT is a kinase inhibitor indicated for the treatment of: Gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. (1.1) Advanced renal cell carcinoma (RCC). (1.2) Progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease. (1.3) 1.1 Gastrointestinal Stromal Tumor (GIST) SUTENT is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. 1.2 Advanced Renal Cell Carcinoma (RCC) SUTENT is indicated for the treatment of advanced renal cell carcinoma. 1.3 Advanced Pancreatic Neuroendocrine Tumors (pNET) SUTENT is indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease.

Launch Date

1.13823357E12
Primary
SUTENT

Approved Use

SUTENT is a kinase inhibitor indicated for the treatment of: Gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. (1.1) Advanced renal cell carcinoma (RCC). (1.2) Progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease. (1.3) 1.1 Gastrointestinal Stromal Tumor (GIST) SUTENT is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. 1.2 Advanced Renal Cell Carcinoma (RCC) SUTENT is indicated for the treatment of advanced renal cell carcinoma. 1.3 Advanced Pancreatic Neuroendocrine Tumors (pNET) SUTENT is indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease.

Launch Date

1.13823357E12
Primary
SUTENT

Approved Use

SUTENT is a kinase inhibitor indicated for the treatment of: Gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. (1.1) Advanced renal cell carcinoma (RCC). (1.2) Progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease. (1.3) 1.1 Gastrointestinal Stromal Tumor (GIST) SUTENT is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. 1.2 Advanced Renal Cell Carcinoma (RCC) SUTENT is indicated for the treatment of advanced renal cell carcinoma. 1.3 Advanced Pancreatic Neuroendocrine Tumors (pNET) SUTENT is indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease.

Launch Date

1.13823357E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4.35 ng/mL
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
N-DESETHYL SUNITINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
51.1 ng/mL
37.5 mg 1 times / day steady-state, oral
dose: 37.5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: ERLOTINIB
SUNITINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
21.9 ng/mL
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SUNITINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
21.3 ng/mL
15 mg/m² 1 times / day steady-state, oral
dose: 15 mg/m²
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUNITINIB plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
559 ng × h/mL
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
N-DESETHYL SUNITINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1056 ng × h/mL
37.5 mg 1 times / day steady-state, oral
dose: 37.5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: ERLOTINIB
SUNITINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1369 ng × h/mL
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SUNITINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
791 ng × h/L
15 mg/m² 1 times / day steady-state, oral
dose: 15 mg/m²
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUNITINIB plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
111 h
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
N-DESETHYL SUNITINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
63.8 h
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SUNITINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
22.7 h
15 mg/m² 1 times / day steady-state, oral
dose: 15 mg/m²
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUNITINIB plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
N-DESETHYL SUNITINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5%
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SUNITINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5%
SUNITINIB plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
50 mg 1 times / day steady, oral (starting)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, 52-77 years
n = 5
Health Status: unhealthy
Condition: Renal Cell Carcinoma
Age Group: 52-77 years
Sex: M+F
Population Size: 5
Sources:
Disc. AE: Thrombocytopenia, Fever...
AEs leading to
discontinuation/dose reduction:
Thrombocytopenia (1 patient)
Fever (1 patient)
Fatigue (1 patient)
Nausea (1 patient)
Vomiting (1 patient)
Sources:
25 mg 1 times / day steady, oral
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
unhealthy, 74 years
n = 1
Health Status: unhealthy
Condition: Renal Cell Carcinoma
Age Group: 74 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Fever...
AEs leading to
discontinuation/dose reduction:
Fever (1 patient)
Sources:
350 mg 1 times / day steady, oral
Highest studied dose
Dose: 350 mg, 1 times / day
Route: oral
Route: steady
Dose: 350 mg, 1 times / day
Sources:
unhealthy
175 mg steady, oral
Studied dose
Dose: 175 mg
Route: oral
Route: steady
Dose: 175 mg
Sources:
unhealthy
Health Status: unhealthy
Condition: advanced solid tumors
Sources:
50 mg 1 times / day steady, oral (starting)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 202
Disc. AE: Anemia, Liver failure...
AEs leading to
discontinuation/dose reduction:
Anemia (4 patients)
Liver failure (2 patients)
Metabolic disorder (3 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Fatigue 1 patient
Disc. AE
50 mg 1 times / day steady, oral (starting)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, 52-77 years
n = 5
Health Status: unhealthy
Condition: Renal Cell Carcinoma
Age Group: 52-77 years
Sex: M+F
Population Size: 5
Sources:
Fever 1 patient
Disc. AE
50 mg 1 times / day steady, oral (starting)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, 52-77 years
n = 5
Health Status: unhealthy
Condition: Renal Cell Carcinoma
Age Group: 52-77 years
Sex: M+F
Population Size: 5
Sources:
Nausea 1 patient
Disc. AE
50 mg 1 times / day steady, oral (starting)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, 52-77 years
n = 5
Health Status: unhealthy
Condition: Renal Cell Carcinoma
Age Group: 52-77 years
Sex: M+F
Population Size: 5
Sources:
Thrombocytopenia 1 patient
Disc. AE
50 mg 1 times / day steady, oral (starting)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, 52-77 years
n = 5
Health Status: unhealthy
Condition: Renal Cell Carcinoma
Age Group: 52-77 years
Sex: M+F
Population Size: 5
Sources:
Vomiting 1 patient
Disc. AE
50 mg 1 times / day steady, oral (starting)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy, 52-77 years
n = 5
Health Status: unhealthy
Condition: Renal Cell Carcinoma
Age Group: 52-77 years
Sex: M+F
Population Size: 5
Sources:
Fever 1 patient
Disc. AE
25 mg 1 times / day steady, oral
Dose: 25 mg, 1 times / day
Route: oral
Route: steady
Dose: 25 mg, 1 times / day
Sources:
unhealthy, 74 years
n = 1
Health Status: unhealthy
Condition: Renal Cell Carcinoma
Age Group: 74 years
Sex: M
Population Size: 1
Sources:
Liver failure 2 patients
Disc. AE
50 mg 1 times / day steady, oral (starting)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 202
Metabolic disorder 3 patients
Disc. AE
50 mg 1 times / day steady, oral (starting)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 202
Anemia 4 patients
Disc. AE
50 mg 1 times / day steady, oral (starting)
Dose: 50 mg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg, 1 times / day
Sources:
unhealthy
n = 202
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
yes [IC50 39 uM]
yes [Ki 110 uM]
yes [Ki 140 uM]
yes [Ki 24 uM]
yes [Ki 28 uM]
yes [Ki 5.4 uM]
yes [Ki 54 uM]
yes [Ki >150 uM]
yes [Ki >150 uM]
yes [Ki >150 uM]
yes [Ki >150 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
minor
minor
minor
minor
moderate
no
no
no
no
no
yes
yes (co-administration study)
Comment: ketoconazole increased auc of sunitinib by 51%
Tox targets

Tox targets

PubMed

PubMed

TitleDatePubMed
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
2003 Jan
Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour.
2006 Jul
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
2006 Oct 14
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
2007 Jan 11
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
2008 Aug 1
Fatal liver failure in a patient on acetaminophen treated with sunitinib malate and levothyroxine.
2009 Apr
Sequential sorafenib and sunitinib for renal cell carcinoma.
2009 Jul
Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
2009 Jun 28
Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.
2009 May
The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity.
2010 Apr 15
Differences in effects on myocardium and mitochondria by angiogenic inhibitors suggest separate mechanisms of cardiotoxicity.
2010 Aug
Synthesis and structure-activity relationship of 6-arylureido-3-pyrrol-2-ylmethylideneindolin-2-one derivatives as potent receptor tyrosine kinase inhibitors.
2010 Jul 1
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
2010 Nov 24
Autophagy plays an important role in sunitinib-mediated cell death in H9c2 cardiac muscle cells.
2010 Oct 1
Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.
2011 Jun
Sunitinib improves chemotherapeutic efficacy and ameliorates cisplatin-induced nephrotoxicity in experimental animals.
2011 May
Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations.
2011 Nov 15
Comprehensive analysis of kinase inhibitor selectivity.
2011 Oct 30
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.
2011 Oct 30
Neutrophil-mediated experimental metastasis is enhanced by VEGFR inhibition in a zebrafish xenograft model.
2012 Aug
Evaluation of subchronic toxicity of SIM010603, a potent inhibitor of receptor tyrosine kinase, after 28-day repeated oral administration in SD rats and beagle dogs.
2012 May
A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-κB signaling in chordoma biology.
2013
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
2013 Apr 15
Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.
2013 Dec
Activity-based kinase profiling of approved tyrosine kinase inhibitors.
2013 Feb
Chloroquine synergizes sunitinib cytotoxicity via modulating autophagic, apoptotic and angiogenic machineries.
2014 Jun 25
Development of cardiac hypertrophy by sunitinib in vivo and in vitro rat cardiomyocytes is influenced by the aryl hydrocarbon receptor signaling pathway.
2014 Mar
Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma.
2015 Dec
Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs.
2015 Jun
Bridging Functional and Structural Cardiotoxicity Assays Using Human Embryonic Stem Cell-Derived Cardiomyocytes for a More Comprehensive Risk Assessment.
2015 Nov
Identification of a Mitochondrial DNA Polymerase Affecting Cardiotoxicity of Sunitinib Using a Genome-Wide Screening on S. pombe Deletion Library.
2016 Jan
Inflammatory and fibrotic processes are involved in the cardiotoxic effect of sunitinib: Protective role of L-carnitine.
2016 Jan 22
Patents

Sample Use Guides

GIST: 50 mg orally once daily, with or without food, 4 weeks on treatment followed by 2 weeks off. pNET: 37.5 mg orally once daily, with or without food, continuously without a scheduled off-treatment period
Route of Administration: Oral
Cell viability assays following suni¬tinib treatment were performed using a cell counting kit 8 (CCK 8; Dojindo Molecular Technologies, Inc., Kumamoto, Japan). PC 3 and LNCaP cells were seeded in 96 well plates (1x104 cells/well) with culture medium supplemented with 10% FBS and were incubated at 37˚C in incubator with an atmosphere of 5% CO2 for 12 h to allow adherence. Cells were treated with 10 μl culture medium containing 0, 5, 10 or 20 μmol/l of sunitinib for 24 h. A total of 10 μl CCK 8 was added to the cells, following sunitinib treatment, and the cells were incubated for a further 2 h at 37˚C. A microplate reader was used to measure the absorbance of each well at 450 nm
Substance Class Chemical
Created
by admin
on Fri Jun 25 22:05:05 UTC 2021
Edited
by admin
on Fri Jun 25 22:05:05 UTC 2021
Record UNII
V99T50803M
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SUNITINIB
EMA EPAR   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
SU-011248
Code English
1H-PYRROLE-3-CARBOXAMIDE, N-(2-(DIETHYLAMINO)ETHYL)-5-((Z)-(5-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)METHYL)-2,4-DIMETHYL-
Systematic Name English
NSC-736511
Code English
SU-11248
Code English
SUNITINIB [WHO-DD]
Common Name English
SUNITINIB [VANDF]
Common Name English
N-(2-(DIETHYLAMINO)ETHYL)-5-((Z)-(5-FLUORO-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE
Systematic Name English
NSC-750690
Code English
SU011248
Code English
SUNITINIB [EMA EPAR]
Common Name English
SUNITINIB [MI]
Common Name English
SUNITINIB [INN]
Common Name English
N-(2-(DIETHYLAMINO)ETHYL)-5-((Z)-(5-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)METHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE
Systematic Name English
Classification Tree Code System Code
WHO-ATC L01XE04
Created by admin on Fri Jun 25 22:05:05 UTC 2021 , Edited by admin on Fri Jun 25 22:05:05 UTC 2021
NDF-RT N0000175076
Created by admin on Fri Jun 25 22:05:05 UTC 2021 , Edited by admin on Fri Jun 25 22:05:05 UTC 2021
EMA ASSESSMENT REPORTS SUTENT (AUTHORIZED: GASTROINTESTINAL STROMAL TUMORS, NEUROENDOCRINE TUMORS, RENAL CELL CARCINOMA)
Created by admin on Fri Jun 25 22:05:05 UTC 2021 , Edited by admin on Fri Jun 25 22:05:05 UTC 2021
NCI_THESAURUS C1971
Created by admin on Fri Jun 25 22:05:05 UTC 2021 , Edited by admin on Fri Jun 25 22:05:05 UTC 2021
NCI_THESAURUS C129825
Created by admin on Fri Jun 25 22:05:05 UTC 2021 , Edited by admin on Fri Jun 25 22:05:05 UTC 2021
NDF-RT N0000175605
Created by admin on Fri Jun 25 22:05:05 UTC 2021 , Edited by admin on Fri Jun 25 22:05:05 UTC 2021
NCI_THESAURUS C1967
Created by admin on Fri Jun 25 22:05:05 UTC 2021 , Edited by admin on Fri Jun 25 22:05:05 UTC 2021
LIVERTOX 917
Created by admin on Fri Jun 25 22:05:05 UTC 2021 , Edited by admin on Fri Jun 25 22:05:05 UTC 2021
WHO-VATC QL01XE04
Created by admin on Fri Jun 25 22:05:05 UTC 2021 , Edited by admin on Fri Jun 25 22:05:05 UTC 2021
Code System Code Type Description
RXCUI
357977
Created by admin on Fri Jun 25 22:05:05 UTC 2021 , Edited by admin on Fri Jun 25 22:05:05 UTC 2021
PRIMARY RxNorm
MESH
C473478
Created by admin on Fri Jun 25 22:05:05 UTC 2021 , Edited by admin on Fri Jun 25 22:05:05 UTC 2021
PRIMARY
EVMPD
SUB22321
Created by admin on Fri Jun 25 22:05:05 UTC 2021 , Edited by admin on Fri Jun 25 22:05:05 UTC 2021
PRIMARY
EPA CompTox
557795-19-4
Created by admin on Fri Jun 25 22:05:05 UTC 2021 , Edited by admin on Fri Jun 25 22:05:05 UTC 2021
PRIMARY
NCI_THESAURUS
C71622
Created by admin on Fri Jun 25 22:05:05 UTC 2021 , Edited by admin on Fri Jun 25 22:05:05 UTC 2021
PRIMARY
HSDB
7932
Created by admin on Fri Jun 25 22:05:05 UTC 2021 , Edited by admin on Fri Jun 25 22:05:05 UTC 2021
PRIMARY
CAS
557795-19-4
Created by admin on Fri Jun 25 22:05:05 UTC 2021 , Edited by admin on Fri Jun 25 22:05:05 UTC 2021
PRIMARY
INN
8646
Created by admin on Fri Jun 25 22:05:05 UTC 2021 , Edited by admin on Fri Jun 25 22:05:05 UTC 2021
PRIMARY
PUBCHEM
5329102
Created by admin on Fri Jun 25 22:05:05 UTC 2021 , Edited by admin on Fri Jun 25 22:05:05 UTC 2021
PRIMARY
LACTMED
Sunitinib
Created by admin on Fri Jun 25 22:05:05 UTC 2021 , Edited by admin on Fri Jun 25 22:05:05 UTC 2021
PRIMARY
ChEMBL
CHEMBL535
Created by admin on Fri Jun 25 22:05:05 UTC 2021 , Edited by admin on Fri Jun 25 22:05:05 UTC 2021
PRIMARY
MERCK INDEX
M10399
Created by admin on Fri Jun 25 22:05:05 UTC 2021 , Edited by admin on Fri Jun 25 22:05:05 UTC 2021
PRIMARY Merck Index
IUPHAR
5713
Created by admin on Fri Jun 25 22:05:05 UTC 2021 , Edited by admin on Fri Jun 25 22:05:05 UTC 2021
PRIMARY
DRUG BANK
DB01268
Created by admin on Fri Jun 25 22:05:05 UTC 2021 , Edited by admin on Fri Jun 25 22:05:05 UTC 2021
PRIMARY
FDA UNII
V99T50803M
Created by admin on Fri Jun 25 22:05:05 UTC 2021 , Edited by admin on Fri Jun 25 22:05:05 UTC 2021
PRIMARY
WIKIPEDIA
SUNITINIB
Created by admin on Fri Jun 25 22:05:05 UTC 2021 , Edited by admin on Fri Jun 25 22:05:05 UTC 2021
PRIMARY
DRUG CENTRAL
2544
Created by admin on Fri Jun 25 22:05:05 UTC 2021 , Edited by admin on Fri Jun 25 22:05:05 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
TRANSPORTER -> SUBSTRATE
TARGET -> INHIBITOR
TRANSPORTER -> INHIBITOR
TARGET -> INHIBITOR
TRANSPORTER -> SUBSTRATE
TARGET -> INHIBITOR
TARGET -> INHIBITOR
INHIBITOR
TARGET -> INHIBITOR
TRANSPORTER -> SUBSTRATE
TARGET -> INHIBITOR
Related Record Type Details
METABOLITE INACTIVE -> PARENT
URINE
METABOLITE ACTIVE -> PARENT
MAJOR
FECAL; PLASMA; URINE
Related Record Type Details
ACTIVE MOIETY